Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celera Group
In an unusual move prompted by an enormous second wave of infections, India is accelerating approvals for COVID-19 vaccines granted emergency use authorizations by other selected regulators or on the WHO’s emergency use list without a local bridging study. While this seems a prelude to permitting private sales, where will the supplies come from?
Sinovac’s COVID-19 vaccine has an efficacy rate of 50% in one hard-hit region of Brazil, a study finds, which could fuel fresh doubts over the efficacy of Chinese vaccines and raise the urgency to change current vaccination strategy.
While preclinical data show boosters to MRNA-1273 can reduce the threat of viral variants, the biotech also told investors it sees no link between its vaccine and thrombotic episodes.
The company’s first candidate is a BCMA-targeting CAR-T, but Arcellx also is developing ARC T-cells controlled by a synthetic protein. Both have a binding domain that may confer better safety and efficacy than competitors.